Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The investigators present a randomised open label phase Ib/IIa trial of nebulised
unfractionated heparin to evaluate the effect of nebulised unfractionated heparin on the
procoagulant response in ICU patients with SARS-CoV-2 requiring advanced respiratory support.
As this is one of the first studies of nebulised heparin in COVID 19 lung disease the
investigators will assess safety as a co-primary outcome.